` GUTS (Fractyl Health Inc) vs S&P 500 Comparison - Alpha Spread

F
GUTS
vs
S&P 500

Over the past 12 months, GUTS has underperformed S&P 500, delivering a return of -55% compared to the S&P 500's +13% growth.

Stocks Performance
GUTS vs S&P 500

Loading
GUTS
S&P 500
Add Stock

Performance Gap
GUTS vs S&P 500

Loading
GUTS
S&P 500
Difference
www.alphaspread.com

Performance By Year
GUTS vs S&P 500

Loading
GUTS
S&P 500
Add Stock

Competitors Performance
Fractyl Health Inc vs Peers

S&P 500
GUTS
539112
SLB
BKR
AMMN
Add Stock

Fractyl Health Inc
Glance View

Market Cap
87.6m USD
Industry
N/A

Fractyl Health Inc is a US-based company operating in industry. The company is headquartered in Lexington, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2024-02-02. Fractyl Health, Inc. is a metabolic therapeutics company. The firm is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company’s lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The firm is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. The company is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.

GUTS Intrinsic Value
1.15 USD
Overvaluation 36%
Intrinsic Value
Price
F
Back to Top